About Lipocine (NASDAQ:LPCN)
Lipocine Inc., a specialty pharmaceutical company, develops pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health. The company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is LPCN 1021, an oral testosterone replacement therapy designed for twice-a-day dosing that has completed Phase 3 testing. The company's pipeline candidates also include LPCN 1111, a next generation oral testosterone therapy product with once daily dosing that is in Phase 2 testing; and LPCN 1107, which has completed Phase 2 testing for the prevention of recurrent preterm birth. Lipocine Inc. is headquartered in Salt Lake City, Utah.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LPCN
CUSIPN/A
Phone801-994-7383
Debt
Debt-to-Equity RatioN/A
Current Ratio3.98%
Quick Ratio3.98%
Price-To-Earnings
Trailing P/E Ratio-1.48
Forward P/E Ratio-1.65
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.89 per share
Price / Book1.74
Profitability
EPS (Most Recent Fiscal Year)($1.05)
Net Income$-20,980,000.00
Net MarginsN/A
Return on Equity-90.49%
Return on Assets-78.57%
Miscellaneous
Employees14
Outstanding Shares21,260,000
Lipocine (NASDAQ:LPCN) Frequently Asked Questions
What is Lipocine's stock symbol?
Lipocine trades on the NASDAQ under the ticker symbol "LPCN."
How were Lipocine's earnings last quarter?
Lipocine (NASDAQ:LPCN) released its quarterly earnings data on Monday, March, 12th. The specialty pharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.04. View Lipocine's Earnings History.
When is Lipocine's next earnings date?
What price target have analysts set for LPCN?
5 brokerages have issued 12 month price targets for Lipocine's shares. Their forecasts range from $2.00 to $38.00. On average, they expect Lipocine's share price to reach $12.80 in the next twelve months. View Analyst Ratings for Lipocine.
Who are some of Lipocine's key competitors?
Some companies that are related to Lipocine include BioDelivery Sciences International (BDSI), Checkpoint Therapeutics (CKPT), Affimed (AFMD), Adamis Pharmaceuticals (ADMP), AcelRx Pharmaceuticals (ACRX), ContraFect (CFRX), Trevena (TRVN), Infinity Pharmaceuticals (INFI), Axovant Sciences (AXON), Otonomy (OTIC), ProQR Therapeutics (PRQR), Merrimack Pharmaceuticals (MACK), Chembio Diagnostics (CEMI), OncoMed Pharmaceuticals (OMED) and Oramed Pharmaceuticals (ORMP).
Who are Lipocine's key executives?
Lipocine's management team includes the folowing people:
- Dr. Mahesh V. Patel Ph.D., Co-Founder, Chairman, Pres & CEO (Age 61)
- Mr. Morgan R. Brown MBA, CPA, Exec. VP, CFO & Corp. Sec. (Age 50)
- Dr. William I. Higuchi Ph.D., Chief Scientific Consultant (Age 87)
- Dr. Anthony DelConte M. D., Chief Medical Director (Age 60)
- Mr. Gregory B. Bass, Exec. VP & Chief Commercial Officer (Age 44)
Has Lipocine been receiving favorable news coverage?
News articles about LPCN stock have been trending somewhat positive recently, Accern reports. The research group rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Lipocine earned a news sentiment score of 0.16 on Accern's scale. They also assigned news coverage about the specialty pharmaceutical company an impact score of 46.14 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Lipocine?
Shares of LPCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lipocine's stock price today?
One share of LPCN stock can currently be purchased for approximately $1.55.
How big of a company is Lipocine?
Lipocine has a market capitalization of $31.90 million. The specialty pharmaceutical company earns $-20,980,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. Lipocine employs 14 workers across the globe.
How can I contact Lipocine?
Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company can be reached via phone at 801-994-7383 or via email at [email protected]
MarketBeat Community Rating for Lipocine (LPCN)
MarketBeat's community ratings are surveys of what our community members think about Lipocine and other stocks. Vote "Outperform" if you believe LPCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPCN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Lipocine (NASDAQ:LPCN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Lipocine in the last 12 months. Their average twelve-month price target is $12.80, suggesting that the stock has a possible upside of 725.81%. The high price target for LPCN is $38.00 and the low price target for LPCN is $2.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.80 | 2.75 | 2.75 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $12.80 | $13.50 | $13.50 | $24.6667 |
| Price Target Upside: | 725.81% upside | 812.16% upside | 621.93% upside | 470.99% upside |
Lipocine (NASDAQ:LPCN) Consensus Price Target History
Lipocine (NASDAQ:LPCN) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Lipocine (NASDAQ:LPCN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Lipocine (NASDAQ LPCN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 11.30%
Institutional Ownership Percentage: 17.78%
Lipocine (NASDAQ LPCN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/29/2017 | Gregory Brooks Bass | Insider | Sell | 3,750 | $3.47 | $13,012.50 | |  |
| 12/29/2017 | Gregory Brooks Bass | Insider | Sell | 3,750 | $3.47 | $13,012.50 | 9,375 | |
| 12/29/2017 | Jeffrey Arvin Fink | Director | Sell | 938 | $3.47 | $3,254.86 | | |
| 12/29/2017 | Mahesh V Patel | CEO | Sell | 6,000 | $3.48 | $20,880.00 | | |
| 12/29/2017 | Mahesh V Patel | CEO | Sell | 6,000 | $3.48 | $20,880.00 | 728,112 | |
| 12/29/2017 | Morgan R Brown | CFO | Sell | 2,813 | $3.47 | $9,761.11 | 26,375 | |
| 12/29/2017 | Morgan R Brown | CFO | Sell | 2,813 | $3.47 | $9,761.11 | | |
| 12/29/2017 | Stephen A Hill | Director | Sell | 1,250 | $3.47 | $4,337.50 | 6,500 | |
| 9/30/2015 | John W Higuchi | Director | Buy | 5,000 | $12.68 | $63,400.00 | 693,382 | |
| 9/30/2015 | Mahesh V. Patel | CEO | Buy | 4,000 | $11.84 | $47,360.00 | 887,632 | |
| 11/25/2014 | Mahesh V Patel | CEO | Buy | 2,000 | $5.10 | $10,200.00 | | |
| 11/24/2014 | Mahesh V Patel | CEO | Buy | 2,000 | $5.45 | $10,900.00 | | |
| 11/19/2014 | Richard Dana Ono | Director | Buy | 4,000 | $5.14 | $20,560.00 | | |
| 11/14/2014 | Mahesh V Patel | CEO | Buy | 2,000 | $5.06 | $10,120.00 | | |
| 11/13/2014 | Mahesh V Patel | CEO | Buy | 2,000 | $5.05 | $10,100.00 | | |
| 11/13/2014 | Stephen A Hill | Director | Buy | 4,000 | $4.95 | $19,800.00 | | |
(Data available from 1/1/2013 forward)
Lipocine (NASDAQ LPCN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Lipocine, Inc ...
globenewswire.com - April 23 at 8:15 AM |
 | Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Lipocine, Inc. -- LPCN
finance.yahoo.com - April 23 at 8:15 AM |
 | Lipocine (LPCN) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 18 at 8:40 AM |
| Lipocine (LPCN) Expected to Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - April 16 at 7:11 AM |
| Lipocine (LPCN) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - April 11 at 3:58 PM |
| Roth Capital Analysts Give Lipocine (LPCN) a $38.00 Price Target
www.americanbankingnews.com - April 10 at 8:23 PM |
| LPCN: Coming at the FDA Like a Spider Monkey
finance.yahoo.com - April 2 at 5:27 PM |
| Canaccord Genuity Reaffirms "Hold" Rating for Lipocine (LPCN)
www.americanbankingnews.com - March 29 at 9:04 PM |
| Seaport Global Securities Initiates Coverage on Lipocine (LPCN)
www.americanbankingnews.com - March 29 at 12:28 PM |
| Lipocine (LPCN) Stock Rating Lowered by Canaccord Genuity
www.americanbankingnews.com - March 28 at 11:32 PM |
| Lipocine Inc (LPCN) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 24 at 8:04 AM |
| Lipocine to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 21 at 8:49 AM |
| HC Wainwright Analysts Give Lipocine (LPCN) a $3.00 Price Target
www.americanbankingnews.com - March 18 at 10:24 AM |
| Lipocine to Present at the Oppenheimer 28th Annual Healthcare Conference
finance.yahoo.com - March 14 at 8:33 AM |
| Lipocine (LPCN) Rating Reiterated by Canaccord Genuity
www.americanbankingnews.com - March 13 at 6:22 PM |
| -$0.26 Earnings Per Share Expected for Lipocine Inc (LPCN) This Quarter
www.americanbankingnews.com - March 13 at 12:19 PM |
| Lipocine (LPCN) Issues Quarterly Earnings Results
www.americanbankingnews.com - March 13 at 10:39 AM |
 | Lipocine Announces Financial and Operational Results for the ... - PR Newswire (press release)
www.prnewswire.com - March 12 at 6:39 PM |
| Lipocine Announces Financial and Operational Results for the Fiscal Year Ended December 31, 2017
finance.yahoo.com - March 12 at 9:03 AM |
| Interested In Lipocine Inc (NASDAQ:LPCN)? Here’s What Its Recent Performance Looks Like
finance.yahoo.com - March 6 at 8:15 AM |
| 373,101 Shares in Lipocine Inc (LPCN) Purchased by Prosight Management LP
www.americanbankingnews.com - March 5 at 4:07 PM |
| Lipocine to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 5 at 8:18 AM |
 | UPDATE: Empire Asset Upgrades Lipocine Inc (LPCN) to Buy, 'Conceivable Approval on PDUFA'
www.streetinsider.com - February 28 at 6:03 PM |
| UPDATE: Empire Asset Upgrades Lipocine Inc (LPCN) to Buy, 'Conceivable Approval on PDUFA' - StreetInsider.com
www.streetinsider.com - February 28 at 8:18 AM |
| Empire Asset Assigns Penny Stock Lipocine $21 Price Target, Buy Rating
finance.yahoo.com - February 27 at 5:54 PM |
| Lipocine Inc (LPCN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - February 27 at 9:52 AM |
| Lipocine (LPCN) to Release Earnings on Monday
www.americanbankingnews.com - February 26 at 3:38 AM |
| Lipocine Inc (LPCN) Expected to Post Earnings of -$0.26 Per Share
www.americanbankingnews.com - February 24 at 9:26 AM |
 | LIPOCINE INVESTIGATION INITIATED BY FORMER...
www.benzinga.com - February 17 at 8:14 AM |
| LIPOCINE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lipocine Inc. - LPCN
finance.yahoo.com - February 17 at 8:14 AM |
| LIPOCINE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lipocine Inc. - LPCN
www.prnewswire.com - February 17 at 12:25 AM |
| Lipocine Announces Settlement of Securities Class Action Lawsuit - PR Newswire (press release)
www.prnewswire.com - February 16 at 8:18 AM |
| Lipocine Announces Settlement of Securities Class Action Lawsuit
finance.yahoo.com - February 16 at 8:18 AM |
| Lipocine Announces $10 Million Loan and Security Agreement with Silicon Valley Bank
finance.yahoo.com - February 8 at 8:11 AM |
| Lipocine to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 8:11 AM |
| Lipocine Inc (LPCN) Expected to Announce Earnings of -$0.26 Per Share
www.americanbankingnews.com - February 7 at 9:52 AM |
| LIPOCINE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lipocine Inc. – LPCN
finance.yahoo.com - February 3 at 9:30 AM |
| Harwood Feffer LLP Announces Investigation of Lipocine Inc.
finance.yahoo.com - January 30 at 9:30 AM |
| Analysts Expect Lipocine Inc (LPCN) Will Announce Earnings of -$0.26 Per Share
www.americanbankingnews.com - January 21 at 11:26 AM |
| LPCN: AdCom Votes 6:13 Against Tlando
finance.yahoo.com - January 19 at 5:57 PM |
| HC Wainwright Reiterates "$3.00" Price Target for Lipocine (LPCN)
www.americanbankingnews.com - January 14 at 12:38 AM |
| Zacks: Analysts Set $9.00 Target Price for Lipocine Inc (LPCN)
www.americanbankingnews.com - January 13 at 1:38 AM |
| LIPOCINE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lipocine, Inc. To Contact The Firm
finance.yahoo.com - January 12 at 5:13 PM |
 | Lipocine's Oral Testosterone Drug Fails To Win FDA Panel Backing
www.nasdaq.com - January 12 at 9:31 AM |
| Pre-Open Movers 01/11: (SECO) (NBEV) (MGI) Higher; (LPCN) (HMNY) (APPN) Lower (more...)
www.streetinsider.com - January 11 at 5:32 PM |
| Adcom Outcome For Lipcocine's Testosterone Drug Punctures Stock; Canaccord Downgrades
www.benzinga.com - January 11 at 5:32 PM |
| After-Hours Stock Movers 01/10: (PRGS) (MFIN) (KBH) Higher; (LPCN) (ARDM) Lower (more...)
www.streetinsider.com - January 11 at 9:43 AM |
| What’s Next For Lipocine After A Disappointing Panel Review?
finance.yahoo.com - January 11 at 9:43 AM |
| Ladenburg Thalmann Financial Services Reaffirms "Buy" Rating for Lipocine (LPCN)
www.americanbankingnews.com - January 11 at 8:38 AM |
 | BRIEF-Lipocine Says FDA's BRUDAC Voted 6 In Favor & 13 Against Benefit/Risk Profile Of Tlando
www.reuters.com - January 10 at 5:22 PM |
Lipocine (NASDAQ:LPCN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Lipocine (NASDAQ:LPCN) Income Statement, Balance Sheet and Cash Flow Statement
Lipocine (NASDAQ LPCN) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
